Every 424B that Autolus Therapeutics plc (AUTL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AUTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUTL filings page.
Autolus Therapeutics plc (AUTL) has filed a resale prospectus covering up to 3,500,000 American Depositary Shares (ADSs), each representing one ordinary share, issuable upon exercise of a warrant held by Perceptive Credit Holdings V, LP. The warrant, issued July 30, 2026, has a cash exercise price of $1.9314 per ADS and expires on July 30, 2036, and may also be exercised on a cashless basis. Autolus is not selling any ADSs in this offering and will receive no proceeds from resales by the selling securityholder, only any cash paid upon warrant exercise. Autolus is a commercial-stage biopharmaceutical company marketing AUCATZYL (obe-cel), a CD19 CAR-T therapy approved for adult relapsed/refractory B‑cell precursor acute lymphoblastic leukemia in the United States, United Kingdom and European Union, and is advancing obe‑cel in pediatric B‑ALL, B‑NHL and autoimmune indications including systemic lupus erythematosus and multiple sclerosis.
Autolus Therapeutics plc filed a prospectus supplement covering the resale by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs), including 3,265,306 ADSs issuable upon exercise of outstanding warrants. The ADSs trade on Nasdaq under the symbol AUTL, and the closing price on January 23, 2026 was $1.46 per ADS.
The supplement also incorporates an 8-K describing a new 10-year Master Supply Agreement between Autolus Limited and AGC Biologics S.p.A for lentiviral vector, a critical raw material for the company’s CAR-T products, including AUCATZYL and clinical trial products. Autolus Limited committed to purchase a minimum of 14 batches of lentiviral vector in the first two calendar years and a minimum value of EUR 25 million of products and services over the subsequent five-year period, under a non-exclusive arrangement that gives AGC a first right to negotiate new manufacturing activities for the obe-cel product.
Autolus Therapeutics plc filed Prospectus Supplement No. 4 covering the resale of up to 54,584,250 ADSs by selling securityholders. This includes 51,318,944 ADSs representing ordinary shares and up to 3,265,306 ADSs issuable upon exercise of outstanding warrants. The ADSs trade on Nasdaq as AUTL; the closing price was $1.50 on November 11, 2025.
The supplement attaches the company’s Q3 2025 report. For the quarter, Autolus recorded $21.1 million in product revenue and a net loss of $79.1 million. As of September 30, 2025, cash and cash equivalents were $86.1 million and marketable securities were $281.3 million. 266,143,286 ordinary shares were outstanding as of November 11, 2025.